Komunikaty PR
ABL Diagnostics Successfully Verifies DeepChek® Assays & Software on Illumina’s MiSeq™ i100 & MiSeqDx Platforms
2025-05-21 | 09:55:06
The verification was conducted across several key microbiology applications with outstanding results, including—but not limited to—HIV drug resistance genotyping (DeepChek®-HIV), tuberculosis drug resistance profiling (DeepChek®-TB), and viral hepatitis genotyping (DeepChek®-HCV). All tests demonstrated high analytical performance, intuitive usability, and seamless integration within the broader DeepChek® ecosystem.
Crucially, the verification of DeepChek® assays and software on the MiSeqDx™ platform—Illumina’s CE-IVD-marked sequencing system—confers an additional regulatory and clinical dimension to the solution. When combined with ABL Diagnostics’ own CE-IVD-marked DeepChek® assays and software, this enables an integrated, fully compliant, end-to-end solution for clinical diagnostics. Laboratories can now benefit from a standardized and validated workflow, from sample preparation to sequencing and data interpretation, tailored for routine patient care applications.
This work complements the existing validation of DeepChek® assays across the full spectrum of Illumina NGS platforms—including iSeq™ 100, MiSeq™, MiSeqDx™, MiniSeq™, and NextSeq™—empowering laboratories to adopt DeepChek® solutions regardless of their current infrastructure or throughput requirements.
All analyses are fully supported within the MicrobioChek platform, developed by ABL Diagnostics. This robust software suite offers an intuitive interface to launch analysis pipelines dedicated to both research and clinical use (available for diagnostics in selected countries), ensuring consistent, high-quality, and actionable insights across all supported pathogens and platforms.
The DeepChek® platform also uniquely enables sample pooling and multiplexing, allowing multiple pathogens and sample types to be processed simultaneously within a single NGS run. This provides significant operational efficiency, cost-effectiveness, and faster turnaround times—especially valuable for laboratories facing high throughput demands.
The MiSeq™ i100, recently introduced by Illumina, further enhances DeepChek® workflows through a number of key innovations:
- Fast turnaround time: Results available in as little as 9 hours—ideal for near-patient or time-sensitive diagnostic settings.
- Room temperature-stable reagents: Simplifies storage and transport logistics—critical for decentralized and resource-limited environments.
- Compact and affordable: Small footprint and reduced capital investment make it accessible for low- to mid-throughput labs worldwide.
“At ABL Diagnostics, we are committed to providing laboratories with a robust, end-to-end microbiology genotyping solution that is agnostic of the sequencing platform,” said Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics. “We initially verified DeepChek® on Illumina systems such as MiSeq™, iSeq™ 100, MiniSeq™, and NextSeq™, and are now pleased to include both the MiSeq™ i100 and MiSeqDx™ in our supported portfolio—bringing enhanced flexibility, regulatory strength, and clinical performance to our customers.”
The Market: ABL Diagnostics Leads the Way in Microbiology Genotyping
The NGS market for microbiology is rapidly expanding, driven by the growing need for fast, scalable, and accurate detection of infectious agents and antimicrobial resistance. ABL Diagnostics now offers the broadest portfolio of microbiology genotyping assays using NGS technology, addressing both routine clinical diagnostics and public health challenges:
- Viruses: HIV, HBV, HCV, HDV, CMV, HSV, HPV, Influenza, RSV, SARS-CoV-2…
- Bacteria & Fungi: Mycobacterium tuberculosis (TB), 16S rRNA, 18S rRNA, and bacterial whole genome sequencing (WGS)
- Emerging targets: Several new assays are in development and will be launched in the coming months.
With unmatched assay breadth, compatibility across all major Illumina platforms, and a powerful, dedicated software suite, ABL Diagnostics offers a future-proof, scalable, and regulatory-ready NGS solution tailored to the evolving demands of clinical microbiology, infectious disease surveillance, and global health diagnostics
ABOUT ABL DIAGNOSTICS
ABL Diagnostics specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping:
- UltraGene – real-time PCR-based molecular detection.
- DeepChek®– DNA sequencing for genotyping.
Expanding Portfolio for Microbiology
Our growing portfolio covers:
- HIV diagnostics – Drug resistance assays, including a Whole Genome Kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B & C – Advanced genotyping and drug resistance analysis
- Microbiome & Taxonomy – 16s/18s RNA-based analysis.
- Other viral & bacterial targets – Comprehensive molecular assays.
Syndromic & Digital Solutions
- Syndromic Real-Time PCR assays (known-how and IP acquired in 2025).
- Nadis®– EMR system used in 200+ hospitals in France for HIV & Hepatitis infected patients management.
ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). For further information, please visit www.abldiagnostics.com.
CONTACTS
ABL Diagnostics SA
72C route de Thionville - 57140 WOIPPY
FRANCE
Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com
Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire
BRAK ZDJĘCIA
2025-06-28 | 03:55:06
Medical Supplierz Showcases Cutting-Edge Medical Equipment from Verified Global Suppliers
At Medical Supplierz, we connect healthcare institutions with cutting-edge medical tech. Our showcase streamlines procurement, boosts supplier visibility & drives global access to innovation.”— Bader Alajeel, CEO of Medical
EIN Newswire
BRAK ZDJĘCIA
2025-06-28 | 03:55:06
Acupressure for Nurses Course Offers 6 CNEs from AHNA
PHOENIX, AZ, UNITED STATES, June 27, 2025 /EINPresswire.com/ -- Nurses for Natural Health is excited to announce the launch of its highly anticipated program, "Acupressure for Nurses," designed to empower nurses with practical skills
EIN Newswire
BRAK ZDJĘCIA
2025-06-28 | 03:55:06
Cook Travel Becomes Trailblazer, Accepting Bitcoin for Tours and Airline Tickets
This groundbreaking move positions Cook Travel as the only major travel agency to embrace cryptocurrency for travel services
NEW YORK, NY, UNITED STATES, June 27, 2025 /EINPresswire.com/ -- Cook Travel will now accept Bitcoin and other cryptocurrencies for premium tours and airline tickets. This groundbreaking move positions Cook Travel as the only major travel agency to embrace cryptocurrency for travel services, offering clients a modern way to book travel experiences.
As a spinoff from the renowned Thomas Cook and a former American Express Representative Excellence Award winner, Cook Travel has specialized in discount First and business-class travel since 1983.
New York Times: “PlanetAmex.com (Cook Travel)… are both reputable consolidators.”
Wall Street Journal: “Established discount travel agencies like Cook Travel… save clients money by passing along volume discounts and finding novel routing options.”
Consumer Reports: “recently offered a nonstop business-class fare for over 40 percent off.”
Over the last five decades, the agency has remained steadfastly committed to providing customers with exceptional concierge service at discounted rates, leveraging savings from consolidator fares and tour packages offered by most major airlines. This unique approach allows Cook Travel to provide significant savings on luxurious travel options, including tours, cruises, and Business Class airline tickets.
“We are thrilled to be at the forefront of the travel industry by accepting Bitcoin,” said Molly O’Brian, spokesperson. “This is not just about staying current with payment trends; it’s about providing our clients with flexible and secure payment options that cater to evolving preferences.”
“Beyond flexible, cutting-edge payment options, we’ve noticed our First and Business class customers increasingly want to deal with a human being. Not with an AI bot or a complicated, spammy booking engine,” O’Brien observes.
In an era where person-to-person service is disappearing, Cook distinguishes itself by assigning every customer an individual luxury travel specialist at no cost. Clients can expect a concierge experience without the hassle of dealing with pesky long wait times and irritating elevator music. The days of hour-long holds are over when dealing with Cook Travel, which also proudly boasts no hidden booking fees.
With its commitment to customer satisfaction and innovation, Cook Travel continues to offer luxury for less for discerning clients. “Our clients are really smart,” O’Brien gushes. “They keep us on our toes, they’re hungry for deals, and now, by accepting Bitcoin and other cybercurrencies, our agency is not only enhancing its service offerings but also setting a new standard in the travel industry.”
About Cook Travel
Founded in 1983, Cook Travel specializes in discounted First and Business Class travel. As a spinoff from Thomas Cook, the agency has established itself as a leader in luxury travel services, ensuring each client receives personalized attention from dedicated travel consultants. Cook Travel offers a wide range of travel options, including tours, cruises, and airline tickets, all at competitive prices.
To learn more, Cook Travel call 800-435-8776 or visit info@cooktravel.net. In Europe email Beata@cooktravel.net.
**Media Contact:**
Blake Cordoves
917 514 6958
blake@cooktravel.net
Więcej ważnych informacji
Jedynka Newserii
Jedynka Newserii
Handel
Komisja Europejska chce wprowadzić ujednolicone przepisy dotyczące wyrobów tytoniowych. Europosłowie mówią o kolejnej nadregulacji
Ministerstwo Zdrowia opracowało nowy projekt przepisów wprowadzających kolejne zakazy dotyczące wyrobów tytoniowych – całkowitą eliminację e-papierosów oraz zakaz aromatów w woreczkach nikotynowych. Najprawdopodobniej w ciągu kolejnych dwóch–trzech lat Polska będzie musiała implementować nową dyrektywę dotyczącą wszystkich produktów tytoniowych, nad którym niebawem ma rozpocząć prace Komisja Europejska. Europosłowie mówią o ryzyku chaosu legislacyjnego, nadregulacji i wskazują na zagrożenia związane z proponowaną podwyżką akcyzy.
E-papierosy i aromatyzowane saszetki nikotynowe mogą zniknąć z rynku. Ministerstwo Zdrowia chce całkowitego zakazu ich sprzedaży
Eksperci apelują do Ministerstwa Zdrowia o zmianę w polityce nikotynowej. Powinna lepiej chronić dzieci i młodzież
Komisja Europejska pracuje nad nową dyrektywą tytoniową. Papierosy w Polsce mogą znacznie podrożeć
Planowana podwyżka akcyzy na e-papierosy skłoni palaczy do wyboru bardziej szkodliwych używek. Wrócą też do tradycyjnych papierosów
Konsument
Za trzy miesiące ruszy w Polsce system kaucyjny. Wątpliwości budzą kwestie rozliczeń i podatków
Zaledwie trzy miesiące zostały do startu systemu kaucyjnego w Polsce. Kaucje obejmą szklane i plastikowe butelki oraz puszki z napojami. To duża zmiana dla producentów napojów, sklepów i konsumentów oraz pośredniczących w zbiórce operatorów systemów kaucyjnego. Na razie przepisy są na tyle niedoprecyzowane, że budzą wiele wątpliwości w kwestii rozliczania podatków czy rozliczeń z operatorami. Producenci będą musieli płacić podatek od niezwróconych butelek, co zwiększy ich koszty.
Transport
Rośnie skala agresji na polskich drogach. Problemem jest nie tylko nadmierna prędkość, ale też jazda na zderzaku
Za kilka dni zaczynają się wakacje, czyli statystycznie najniebezpieczniejszy czas na drogach. Wśród głównych przyczyn takich zdarzeń na prostych odcinkach drogi są nadmierna prędkość i jazda na zderzaku. Zarządca autostrady A4 Katowice–Kraków w ramach kampanii „Nie zderzakuj. Posłuchaj. Jedź bezpiecznie” zwraca uwagę na zjawisko agresji na polskich drogach i przypomina, że bezpieczeństwo zaczyna się od osobistych decyzji kierowcy.
Partner serwisu
.gif)
Szkolenia
Akademia Newserii
Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.
|
|
|